Regeneron (REGN): analysis in plain words
Is Regeneron cheap or expensive? How it makes money, whether it grows and its risks, explained in plain words and with its official accounts.
Regeneron (REGN) is listed on the Nasdaq and we classify it in healthcare and pharma. Below are its key dated figures, how it makes money, how it compares with its sector, what works for and against Regeneron according to those figures, and the questions people ask most about the stock. No buy or sell tips.
Regeneron (REGN) key figures as of November 4, 2026
| Figure | Value | What it measures |
|---|---|---|
| Share price | $930.67 | Last price on November 4, 2026 |
| P/E ratio (TTM) | 20.6x | Price over earnings per share |
| Revenue growth | +36.3% | Latest quarter vs the same quarter a year earlier |
| Net margin (TTM) | 28.5% | Profit for every 100 of sales |
| Net debt / EBITDA | Net cash (more cash than debt) | Years of operating profit to repay debt |
| Dividend yield | 0.39% | Annual dividend over price |
| Market cap | $96.3 billion | What the stock market values it at |
The Regeneron figures come from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026. Any REGN figure that is not available shows as N/A: we do not estimate it.
How Regeneron makes money
Regeneron is a biotech company built on antibody drugs. It earns money from U.S. sales of Eylea for retinal eye disease and from its partnership with Sanofi on Dupixent, used for eczema and asthma, which the two companies share profits on. It also sells the cancer immunotherapy Libtayo.
Over the last 12 months, Regeneron brought in revenue of $16.9 billion. For every 100 it sells, Regeneron keeps 46.7 after the direct cost of what it sells (gross margin) and 40.5 after all operating costs (operating margin). With 15,410 full-time employees, that is about $1 million of revenue per employee.
Regeneron against its sector
To know whether a Regeneron figure is high or low you have to put it next to similar companies. This table compares Regeneron with the median of the 30 healthcare and pharma companies Fintols covers, with data as of November 4, 2026.
| Figure | Regeneron | healthcare and pharma median |
|---|---|---|
| P/E | 20.6x | 31.3x (30) |
| Revenue growth | +36.3% | +8.3% (33) |
| Net margin | 28.5% | 14.9% (33) |
| Dividend yield | 0.39% | 1.52% (33) |
| Net debt / EBITDA | -1.2x | 1.6x (31) |
In short, against the typical healthcare and pharma company, Regeneron trades on a lower P/E, grows faster and earns a wider margin. By size, Regeneron ranks number 21 of 28 healthcare and pharma companies quoted in USD on Fintols.
The bull case for Regeneron
What works in favour of Regeneron, according to its figures as of November 4, 2026:
- Regeneron grew sales +36.3% in its latest quarter against the same quarter a year earlier, while the median healthcare and pharma company Fintols tracks grew +8.3%.
- Regeneron keeps 28.5 of every 100 it sells as net profit, against 14.9 for the median healthcare and pharma company: a margin like that leaves money to invest, buy back shares or pay dividends.
- Analysts expect Regeneron earnings to rise: its P/E on the next 12 months of estimated earnings is 13.2x, below the current 20.6x.
The main risk for Regeneron
The Regeneron figures as of November 4, 2026 show no clear red flag (no heavy debt, no losses, no falling sales). Its main risk is the one built into its business: a key drug losing patent protection or a clinical trial failing, plus government pressure on prices.
Frequently asked questions about Regeneron
Is it a good time to buy Regeneron stock?
Fintols does not tell you whether to buy or sell Regeneron, and nobody knows what the price will do tomorrow. What we can show you is where it stands today. As of November 4, 2026, Regeneron stock trades at $930.67, 6% below its 52-week high ($991.73) and 57% above its low ($591.52). Its P/E is 20.6x against a healthcare and pharma median of 31.3x, and 13.2x on the earnings analysts expect over the next 12 months. With Regeneron, as with any stock, timing matters less than understanding the business, investing for the long run and not betting everything on a single company.
Does Regeneron pay a dividend?
Yes. As of November 4, 2026, Regeneron pays $3.76 per share a year, which at today's price is a yield of 0.39%. It uses 8% of its profit to pay it, which leaves room to keep paying it if profit dips. The healthcare and pharma median on Fintols is 1.52%.
Is Regeneron stock expensive?
It depends on what you compare it with. On P/E, Regeneron trades at 20.6x its last 12 months of earnings: cheaper than the healthcare and pharma median (31.3x). Including its debt, Regeneron is valued at 16.1x its EBITDA (EV/EBITDA). A high P/E alone does not make Regeneron expensive: it can be justified if earnings grow fast, and a low one can reflect a business in trouble.
Who are Regeneron's competitors?
On Fintols we compare Regeneron with Cigna, Elevance Health and Zoetis, which are also in healthcare and pharma. As of November 4, 2026, Cigna is worth $80.7 billion and trades on a P/E of 12.6; Elevance Health is worth $94.2 billion and trades on a P/E of 18.4; Zoetis is worth $36.9 billion and trades on a P/E of 14.7. Each has a side-by-side comparison with Regeneron below.
Regeneron competitors
- Cigna (CI) analysis · Regeneron vs Cigna comparison
- Elevance Health (ELV) analysis · Regeneron vs Elevance Health comparison
- Zoetis (ZTS) analysis · Regeneron vs Zoetis comparison
To understand Regeneron better
- DCF and WACC Explained: A Practical Valuation Guide
- P/E Ratio and EPS Explained: How to Read Them Without Traps
More companies like Regeneron: healthcare and pharma stocks and S&P 500 companies. Open the full REGN analysis with its valuation and scenarios. Educational content about Regeneron, not investment advice.